All In Biotech

Drug Trial Radar · NCT06827457

A Study of Safety, Tolerability, PK, and PD of Subcutaneous GenSci120 in Healthy Adults.

A Single-center, Randomized, Double-blind, Placebo-controlled, Dose-escalation Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Subcutaneous Injection of GenSci120 in Healthy Adult Participants in China

Last checked: Nov 20, 2026Latest source record: Dec 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

58

Actual

Start

Feb 20, 2025

Primary completion

Nov 27, 2025

Study completion Dec 16, 2025

Sponsor

Sponsor type
Industry
First posted
Feb 14, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Other
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is designed to evaluate the safety, tolerability, PK and PD of GenSci120 in a randomized, double-blind, placebo-controlled trial involving healthy adult participants.

Conditions

  • Autoimmune Disease

Interventions

  • GenSci120Drug

    Administered SC.

  • PlaceboDrug

    Administered SC.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and severity of treatment-emergent adverse events (TEAEs)Time frame: 113 days
  2. Incidence and severity of serious adverse events (SAEs)Time frame: 113 days
  3. Clinically significant changes from baselineTime frame: 113 days
  4. Concentration of GenSci120 in plasma samples.Time frame: 113 days
  5. Pharmacokinetics-AUC0-lastTime frame: 113 days
  6. Pharmacokinetics-AUC0-infTime frame: 113 days
  7. Pharmacokinetics-TmaxTime frame: 113 days
  8. Pharmacokinetics-CmaxTime frame: 113 days
  9. Pharmacokinetics-CL/FTime frame: 113 days
  10. Pharmacokinetics-t1/2Time frame: 113 days
  11. flow cytometryTime frame: 113 days
  12. Incidence and the time of anti-drug antibody (ADA) positive and neutralizing antibody (NAb) positive (if applicable) after GenSci120 administration.Time frame: 113 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Huashan Hospital

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.